- Jun 19
- 8 min read
Updated: 3 days ago
Table of Contents |
Patient Overview:
At 64 years old, Elena Rossi (alias), a woman from Italy, had spent nearly a decade living with multiple myeloma, a cancer of plasma cells found in the bone marrow. Despite undergoing previous treatments, her disease continued to relapse, leaving her and her family searching for another option.
In September 2019, Anna traveled to China after learning about an investigational CAR T-cell therapy program available at a JCI-accredited hospital in Beijing. Following a comprehensive evaluation by the hospital’s International Center and hematology specialists, she was considered eligible to participate in a clinical trial targeting multiple myeloma.
A Life That Kept Getting Interrupted
Elena grew up in northern Italy. She had a full life — a family, connections, the particular rhythms of a life well-lived — before illness entered it uninvited in her mid-fifties.
She was not the kind of person who surrendered easily to anything. Those who knew her described a woman with practicality and warmth in equal measure. She had navigated decades of life's ordinary complications with equanimity. She assumed she would navigate this, too.
What she could not have known, at the beginning, was how long and how relentless the navigation would be.
A Diagnosis That Kept Coming Back
Multiple myeloma is a cancer of the plasma cells — the cells in the bone marrow responsible for producing antibodies. It is not a single, static disease. It moves. It adapts. And in many patients, it has a particular cruelty: it responds to treatment, retreats, and then — often within months or a few years — it comes back.
Elena was diagnosed in her mid-fifties. Her doctors began treatment. She responded. Then relapse. More treatment. Another response. Another relapse. This cycle — remission followed by return, hope followed by setback — repeated itself across nine years.
By 2019, the cycle had worn through most of the available options in European oncology. Her myeloma had become what clinicians call relapsed and refractory: it had returned despite treatment, and was no longer meaningfully responding to the drugs that had previously worked. The options her European care team could offer were narrowing.
“The doctors at home had done everything they could. But the disease kept finding a way around it.”
The prognosis for relapsed, refractory multiple myeloma at this stage is sobering. It was not something Elena had illusions about. She began, quietly and with great urgency, to look for a different path.
The Leap of Faith
It was through her own research that Elena came across something she had not encountered in Europe: CAR-T cell therapy — specifically, a form targeting BCMA (B-cell Maturation Antigen), a protein found on the surface of myeloma cells.
CAR-T therapy — Chimeric Antigen Receptor T-cell therapy — is not chemotherapy. It does not work by poisoning cells indiscriminately. Instead, a patient's own immune cells are removed, reengineered in a laboratory to identify and attack cancer cells specifically, then returned to the body as a living, targeted weapon. For multiple myeloma, BCMA-targeted CAR-T represented one of the most promising precision approaches anywhere in the world.
What she also found was that China had quietly become the global leader in active CAR-T clinical trials — surpassing even the United States. One specialized blood disease centre in the Beijing region stood out: a JCI-accredited hospital with decades of experience in hematology, one of the most active CAR-T research programs on the planet, and a track record of treating international patients.
Elena arrived in China on September 16, 2019. She had no certainty about what she would find. She knew only that she was not ready to stop.
The Treatment Journey
First Meetings
At a JCI-accredited specialist blood disease hospital in the Beijing region, Elena's case was reviewed at the highest level. The hospital director and Dr. Yang — the lead physician heading the hematology ward where Elena was admitted — convened multiple discussions with their medical team to assess whether she was a suitable candidate for the hospital's BCMA-CAR-T clinical trial.
The process was deliberate. Elena's nine-year history of treatment, relapse, and resistance was reviewed in full. The question was not simply whether CAR-T could help her — it was whether her specific disease profile matched the requirements of the trial, and whether her body was in a condition to undertake it safely.
Their conclusion: yes. Elena was enrolled in the BCMA-CAR-T clinical trial for multiple myeloma.
Understanding the Treatment
BCMA — B-cell Maturation Antigen — is a protein that myeloma cells carry on their surface in large quantities. In this clinical trial, Elena's own T-cells (a type of white blood cell central to immune defence) were collected, sent to a specialist laboratory, and genetically modified to carry a new receptor: one designed to lock onto BCMA wherever it appeared. These reengineered cells — now called CAR-T cells — were then multiplied in large numbers and prepared for reinfusion.
The logic is elegant and precise: the modified cells circulate through the body, seek out cells carrying the BCMA protein, bind to them, and destroy them. Unlike standard chemotherapy, which affects healthy cells as well as cancerous ones, this approach is designed to be selective — to find the myeloma cells specifically.
The Day of Infusion
On October 23rd, Elena received her BCMA-CAR-T cell infusion in Ward Two of the hematology department.
The international coordination team at the hospital had served as her bridge throughout — not just translating language, but translating the logic of every step, so that a woman far from home, navigating a healthcare system she had no prior experience with, could make fully informed decisions about her own treatment at every point.
The care team monitored her closely. In CAR-T therapy, the period following infusion is critical: the immune system's response unfolds gradually, and the medical team watches for both signs of response and any side effects that require management.
A Milestone She Did Not Know She Was Making
What Elena did not know — or perhaps did not think about, in the quiet of that ward — was that she had just made a small piece of medical history.
She was the 700th patient enrolled in this hospital's CAR-T clinical trial programme.
The 600th patient had been a seven-year-old boy from Guangdong Province, treated just four months earlier in June for acute B-cell lymphoblastic leukemia (B-ALL) — a cancer of the blood and bone marrow. He had gone on to complete a bridging stem cell transplant, been discharged from hospital, and was in outpatient follow-up, doing well.
Four months. One hundred patients. A seven-year-old child and a 64-year-old woman from Italy. Leukemia and myeloma. The breadth of what CAR-T therapy was becoming — and what this hospital was helping to demonstrate — was visible in the distance between those two cases.
As for Elena's own outcome: her infusion was completed without complication. The monitoring period began. In CAR-T therapy, results reveal themselves over weeks and months, not days. At the time of her treatment, the team expressed genuine, measured optimism.
The road ahead remained uncertain — as it always does. But for the first time in years, there was a road.
What This Story Means
Elena's story is not a story about a miracle. It is a story about refusing to accept a ceiling — and about the quiet courage it takes to cross an ocean when you have run out of options closer to home.
For people living with relapsed and refractory blood cancers, the frontier of what is possible is still being written. Sometimes, it is being written in places you didn't expect — in wards and laboratories quietly doing work that the rest of the world is only beginning to notice.
Understanding the Broader Development of CAR T Therapy
CAR T-cell therapy has become one of the most rapidly evolving areas of cancer immunotherapy.
According to published industry reports available at the time, China and the United States were leading global CAR T clinical research, with China conducting a large number of ongoing clinical trials.
Researchers have also continued exploring new antigen targets, allowing CAR T technology to be investigated across a wider range of blood cancers and, potentially, additional malignancies.
What Patients Say About ChinaCureLink & Medebound HEALTH
ChinaCureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions (FAQ)
Why do some international patients choose China for CAR T-cell therapy?
China has become one of the world's leading centers for CAR T-cell research and clinical development. Many hospitals offer extensive experience treating blood cancers with CAR T-cell therapy through approved treatments and clinical trials. Some international patients travel to China to explore additional treatment options when standard therapies have been exhausted or are not readily available in their home countries.
Is CAR T-cell therapy in China available to international patients?
Yes, some Chinese hospitals accept eligible international patients. Before treatment, patients typically submit their medical records for review by a multidisciplinary team to determine whether they may qualify for an approved CAR T-cell therapy or a clinical trial.
Why was Elena considered eligible for treatment in China?
After living with relapsed multiple myeloma for nine years, Elena's medical records were reviewed by hematology specialists at a JCI-accredited hospital in Beijing. Based on her disease history and clinical evaluation, she met the eligibility criteria for a BCMA-targeted CAR T-cell clinical trial.
Are CAR T-cell clinical trials in China only for Chinese citizens?
No. Some clinical trials and treatment programs accept qualified international patients, although eligibility varies by study protocol, regulatory requirements, and individual medical circumstances.
What medical records are usually required before traveling to China?
Most hospitals request recent pathology reports, bone marrow biopsy results (when applicable), laboratory test results, imaging studies, previous treatment records, medication history, and a summary from the patient's treating physician. These documents allow specialists to evaluate whether CAR T-cell therapy may be appropriate.
How long should international patients expect to stay in China for CAR T-cell therapy?
The total length of stay varies depending on the treatment protocol and the patient's recovery. Many patients should plan for several weeks, which may include medical evaluation, cell collection, laboratory manufacturing of CAR T cells, preparative chemotherapy, CAR T-cell infusion, and post-treatment monitoring before returning home.
What support is available for international patients traveling to China?
Many international patients require assistance beyond medical care, including medical record translation, physician consultations, visa guidance, travel planning, accommodation arrangements, interpretation services, and follow-up coordination. ChinaCureLink serves as a medical travel facilitation service to help coordinate these non-clinical aspects of care while all medical decisions remain the responsibility of licensed physicians.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCureLink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made in consultation with a qualified oncologist who has reviewed your complete medical history and current diagnostic information.
Disclaimer
This case study is intended for educational and informational purposes only. Individual treatment outcomes vary based on many factors, including disease characteristics, overall health, prior therapies, and response to treatment. Participation in clinical trials is subject to strict eligibility criteria determined by qualified physicians.
ChinaCureLink is a medical travel facilitation service and does not provide medical diagnosis, treatment, or clinical recommendations. All medical decisions are made by licensed healthcare professionals.
Comments